182 related articles for article (PubMed ID: 33925109)
41. The aspartate metabolism pathway is differentiable in human hepatocellular carcinoma: transcriptomics and (13) C-isotope based metabolomics.
Darpolor MM; Basu SS; Worth A; Nelson DS; Clarke-Katzenberg RH; Glickson JD; Kaplan DE; Blair IA
NMR Biomed; 2014 Apr; 27(4):381-9. PubMed ID: 24497316
[TBL] [Abstract][Full Text] [Related]
42. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression.
Li YC; Yang CS; Zhou WL; Li HS; Han YJ; Wang QS; Wu HB
World J Gastroenterol; 2018 Jan; 24(4):494-503. PubMed ID: 29398870
[TBL] [Abstract][Full Text] [Related]
43. (1)H-NMR-based metabolomics of tumor tissue for the metabolic characterization of rat hepatocellular carcinoma formation and metastasis.
Wang J; Zhang S; Li Z; Yang J; Huang C; Liang R; Liu Z; Zhou R
Tumour Biol; 2011 Feb; 32(1):223-31. PubMed ID: 20890798
[TBL] [Abstract][Full Text] [Related]
44. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II.
Ong LC; Jin Y; Song IC; Yu S; Zhang K; Chow PK
Acta Radiol; 2008 Dec; 49(10):1145-53. PubMed ID: 18979289
[TBL] [Abstract][Full Text] [Related]
45. (4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies.
Baek S; Mueller A; Lim YS; Lee HC; Lee YJ; Gong G; Kim JS; Ryu JS; Oh SJ; Lee SJ; Bacher-Stier C; Fels L; Koglin N; Schatz CA; Dinkelborg LM; Moon DH
J Nucl Med; 2013 Jan; 54(1):117-23. PubMed ID: 23232273
[TBL] [Abstract][Full Text] [Related]
46. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Very Early and Early Hepatocellular Carcinoma.
Hwang SH; Lee JW; Cho HJ; Kim KS; Choi GH; Yun M
Clin Nucl Med; 2017 Jan; 42(1):34-39. PubMed ID: 27775949
[TBL] [Abstract][Full Text] [Related]
47. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
[TBL] [Abstract][Full Text] [Related]
48. Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE.
Song HJ; Cheng JY; Hu SL; Zhang GY; Fu Y; Zhang YJ
Clin Radiol; 2015 Feb; 70(2):128-37. PubMed ID: 25459673
[TBL] [Abstract][Full Text] [Related]
49. FDG-PET predicts outcomes of treated bone metastasis following palliative radiotherapy in patients with hepatocellular carcinoma.
Choi SH; Chang JS; Jeong YH; Lee Y; Yun M; Seong J
Liver Int; 2014 Aug; 34(7):1118-25. PubMed ID: 24528941
[TBL] [Abstract][Full Text] [Related]
50. PET Imaging of Hepatocellular Carcinomas:
Zhao J; Zhang Z; Nie D; Ma H; Yuan G; Su S; Liu S; Liu S; Tang G
Mol Imaging; 2019; 18():1536012118821032. PubMed ID: 30799682
[TBL] [Abstract][Full Text] [Related]
51. Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma.
Paudyal B; Oriuchi N; Paudyal P; Tsushima Y; Higuchi T; Miyakubo M; Ishikita T; Nakajima T; Endo K
Ann Nucl Med; 2008 Jan; 22(1):83-6. PubMed ID: 18250992
[TBL] [Abstract][Full Text] [Related]
52. The importance of acetyl coenzyme A synthetase for 11C-acetate uptake and cell survival in hepatocellular carcinoma.
Yun M; Bang SH; Kim JW; Park JY; Kim KS; Lee JD
J Nucl Med; 2009 Aug; 50(8):1222-8. PubMed ID: 19617323
[TBL] [Abstract][Full Text] [Related]
53. Metabolic profiling of normal hepatocyte and hepatocellular carcinoma cells via
Chen Y; Chen Z; Feng JH; Chen YB; Liao NS; Su Y; Zou CY
Cell Biol Int; 2018 Apr; 42(4):425-434. PubMed ID: 29144590
[TBL] [Abstract][Full Text] [Related]
54. Prognostic Significance of ¹⁸F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study.
Lee JW; Oh JK; Chung YA; Na SJ; Hyun SH; Hong IK; Eo JS; Song BI; Kim TS; Kim DY; Kim SU; Moon DH; Lee JD; Yun M
J Nucl Med; 2016 Apr; 57(4):509-16. PubMed ID: 26742711
[TBL] [Abstract][Full Text] [Related]
55. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma.
Wudel LJ; Delbeke D; Morris D; Rice M; Washington MK; Shyr Y; Pinson CW; Chapman WC
Am Surg; 2003 Feb; 69(2):117-24; discussion 124-6. PubMed ID: 12641351
[TBL] [Abstract][Full Text] [Related]
56. Comparison of [18F]FDG uptake and distribution with hypoxia and proliferation in FaDu human squamous cell carcinoma (hSCC) xenografts after single dose irradiation.
Bruechner K; Bergmann R; Santiago A; Mosch B; Yaromina A; Hessel F; Hofheinz F; van den Hoff J; Baumann M; Beuthien-Baumann B
Int J Radiat Biol; 2009 Sep; 85(9):772-80. PubMed ID: 19657862
[TBL] [Abstract][Full Text] [Related]
57. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses.
Ho CL; Yu SC; Yeung DW
J Nucl Med; 2003 Feb; 44(2):213-21. PubMed ID: 12571212
[TBL] [Abstract][Full Text] [Related]
58. Detection of Myocardial Metabolic Abnormalities by 18F-FDG PET/CT and Corresponding Pathological Changes in Beagles with Local Heart Irradiation.
Yan R; Song J; Wu Z; Guo M; Liu J; Li J; Hao X; Li S
Korean J Radiol; 2015; 16(4):919-28. PubMed ID: 26175594
[TBL] [Abstract][Full Text] [Related]
59. Clinical applications and advances of positron emission tomography with fluorine-18-fluorodeoxyglucose (18F-FDG) in the diagnosis of liver neoplasms.
He YX; Guo QY
Postgrad Med J; 2008 May; 84(991):246-51. PubMed ID: 18508981
[TBL] [Abstract][Full Text] [Related]
60. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET.
Torizuka T; Tamaki N; Inokuma T; Magata Y; Sasayama S; Yonekura Y; Tanaka A; Yamaoka Y; Yamamoto K; Konishi J
J Nucl Med; 1995 Oct; 36(10):1811-7. PubMed ID: 7562048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
